Lilly strikes up to $5.9B cancer deal with Stipple Bio
Eli Lilly continues to be pharma’s biggest shopaholic. Lilly has enlisted Cambridge, MA-based startup Stipple Bio for a multibillion-dollar deal to develop new cancer treatments, marking what appears to be the Indianapolis drug giant’s second-largest ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.